The UroVysion F.I.S.H. test compared to standard cytology for surveillance of non-muscle invasive bladder cancer.
OBJECTIVE
To evaluate the potential contribution of urinary fluorescent in situ hybridization in the prediction of the risk of recurrence and progression of men undergoing followup for NMIBC.


METHODS
Patients with a history of NMIBC being followed with urinary cytology and cystoscopy were included in the study. Patients with Carcinoma in situ or tumour stage higher than pT1 were excluded from this analysis. F.I.S.H. Test consisted in the UroVysion kit, able to detect four chromosomal abnormalities, specifically, 9p21, Ch 3, 7 and 17.


RESULTS
Of a total of 133 evaluable patients that constitute the subject of the present report 87 patients had a positive urinary F.I.S.H. At a median follow up time of 36 mos 58 patients underwent recurrence (43.6%). In this group 42 (72.6%) and 27 (46.6%) patients had a positive F.I.S.H. and UC, respectively (p = 0.005). A total of 17 patients (12.8%) underwent progression of stage or grade; of those with a positive F.I.S.H. Test and positive UC were 14 (82.4%) and 8 (47.1%), respectively (p = 0.049).


CONCLUSIONS
In patients with history of NMIBC, F.I.S.H. showed a statistically significantly greater capability that UC in identifying patients with recurrence and progression of disease.
Maffezzini
Massimo
M
Struttura Complessa di Urologia, Ospedali Galliera, Genova, Italy. massimo.maffezzini@galliera.it
Capponi
Giacomo
G
Casazza
Stefania
S
Campodonico
Fabio
F
Bandelloni
Roberto
R
Puntoni
Matteo
M
D000368:Aged; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D009361:Neoplasm Invasiveness; D011159:Population Surveillance; D001749:Urinary Bladder Neoplasms / Q000473:pathology*